NVCT Healthcare

Nuvectis Pharma, Inc.

$19.34+0.83%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 631.3M USD
Enterprise value: 607.9M USD
Full-time employees: 16

Overall health

Not enough data: too little is reported yet for an overall view

Only 1 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 114% from December 2022 to July 2026.
Nuvectis Pharma had 114% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Nuvectis Pharma had 114% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Nuvectis Pharma looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Nuvectis Pharma reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

—

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 22.8% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-4.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-3.1%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield1.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Nuvectis Pharma

Is Nuvectis Pharma getting weaker?: Its latest SEC filing (Aug 4, 2026) got weaker in some ways: share count up 22.8%.
How is Nuvectis Pharma valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -4.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.4% vs peers 1.5% (weaker than 100% of peers).
Is Nuvectis Pharma growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Nuvectis Pharma?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Nuvectis Pharma?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 22.8% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Net income (12 months)	−27.2M USD	−27.8M USD	+2.5%
Cash	25.1M USD	22.2M USD	−11.8%
Shares outstanding	26.5M	32.6M	+22.8%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-193.6%	-93.5%	-116.0%	-102.1%	-83.4%	▲ 19 pts
Return on equity (ROE)	—	-134.2%	-182.4%	-195.6%	-143.6%	▲ 52 pts
Current ratio	2.41×	3.30×	2.75×	2.09×	2.38×	▲ 14%

NVCT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Shareholders being diluted. Shares outstanding up 114% from December 2022 to July 2026.

Nuvectis Pharma had 114% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Nuvectis Pharma had 114% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Nuvectis Pharma looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Nuvectis Pharma reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Nuvectis Pharma

Is Nuvectis Pharma getting weaker?

Its latest SEC filing (Aug 4, 2026) got weaker in some ways: share count up 22.8%.

How is Nuvectis Pharma valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -4.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.4% vs peers 1.5% (weaker than 100% of peers).

Is Nuvectis Pharma growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Nuvectis Pharma?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Nuvectis Pharma?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Previous quarter

Latest quarter

Change

Net income (12 months)

−27.2M USD

−27.8M USD

+2.5%

Cash

25.1M USD

22.2M USD

−11.8%

Shares outstanding

26.5M

32.6M

+22.8%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-193.6%

-93.5%

-116.0%

-102.1%

-83.4%

▲ 19 pts

Return on equity (ROE)

—

-134.2%

-182.4%

-195.6%

-143.6%

▲ 52 pts

Current ratio

2.41×

3.30×

2.75×

2.09×

2.38×

▲ 14%